Melinta Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

MORRISTOWN, N.J., May 09, 2019 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company, developing and commercializing novel antibiotics to treat serious bacterial infections, today reported financial results and provided a business update for the first quarter ended March 31, 2019.